CAPR
Capricor Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
- Capricor Therapeutics is developing deramiocel (CAP-1002), an investigational cell therapy for Duchenne muscular dystrophy.Oct 10, 2026
- Capricor reported positive 24-month HOPE-3 extension data for deramiocel in Duchenne muscular dystrophy, showing slower functional decline versus natural history.Oct 5, 2026
FDA designations
Nothing here yet
News
- Capricor Therapeutics announced an extension of the PDUFA target action date as the FDA continued its review of the deramiocel BLAAug 25, 2026
- Capricor Therapeutics provided an update on the FDA advisory committee meeting for deramiocelJul 31, 2026
- The Lancet published HOPE-3 trial data for Capricor Therapeutics’ deramiocel in Duchenne muscular dystrophyJul 31, 2026
- Capricor announced a late-breaking presentation of Phase 3 HOPE-3 results at the 2026 AAN Annual MeetingApr 23, 2026
- Capricor Therapeutics announced the establishment of a new PDUFA date for the deramiocel BLAMar 11, 2026